Dr. Jain on the Activity of Venetoclax in MCL

Video

Preetesh Jain, MD, PhD, discusses the activity of venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Preetesh Jain, MD, PhD, clinical fellow in medical oncology at The University of Texas MD Anderson Cancer Center, discusses the activity of venetoclax (Venclexta) in mantle cell lymphoma (MCL).

In a single-center phase 1 study, investigators evaluated the activity of venetoclax in patients with MCL. In the trial, investigators reached a dose of 800 mg.

The highest complete remission rate of 21% was reported in the cohort of patients with MCL, says Jain. These data speak to the activity of venetoclax in MCL, despite the fact that these patients had not progressed on a BTK inhibitor, concludes Jain.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD